OpenBilldrug price receipt

NADAC week of 2026-10-14

EFAVIRENZ-EMTRICITABINE-TENOFOV DISOP FUM 600-200-300 MG TAB

For 30 tablets

Pharmacies pay

$33.75 filed

30 × $1.12492 per EA

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare

We don’t know yet

No Medicare reference price. Part D: OpenBill did not match this NDC to a usable Medicare Part D spending row. Either Part D has none for it, or the rows that share its name could not safely be tied to it (for example, they mix units, routes or release forms, or the drug is sold over the counter, which Part D does not cover). Part B: This NDC is not in the current quarter’s Medicare Part B NDC-HCPCS crosswalk, so it has no Part B payment limit.


The spread

We don’t know yet

There is no Medicare figure to compare with, so there is no spread.

Cost-plus estimate

$43.81 estimated

$33.75 + $5.06 (15%) + $5.00 fee per fill = $43.81

This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out

OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17)

Open the interactive card Change the quantity, type what you were charged, and see every record in full.

What it is

EFAVIRENZ-EMTRICITABINE-TENOFOV DISOP FUM 600-200-300 MG TAB is how the CMS NADAC file names this product. The FDA NDC Directory lists it as efavirenz, emtricitabine and tenofovir disoproxil fumarate.

FDA gives its dosage form as tablet, film coated and its route as oral.

FDA lists 6 labelers (the companies named on the label) for its NDCs, among them Teva Pharmaceuticals USA, Inc., Camber Pharmaceuticals, Inc. and Macleods Pharmaceuticals Limited.

FDA lists it under 3 Established Pharmacologic Classes: Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor, Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor and Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor.

The NADAC file of 2026-10-14 prices it under 7 NDCs (National Drug Codes); the FDA directory lists 6 of them.

NADAC classes it as a generic drug (rate-setting class G), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $33.75 for 30 tablets (30 × $1.12492 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation code for it: 1, calculated from the most recently completed pharmacy survey.

The 6 labelers

LabelerNDCsPharmacies pay per unit
Aurobindo Pharma Limited1$1.12492 per EA filed
Camber Pharmaceuticals, Inc.1$1.12492 per EA filed
Cipla USA Inc.1$1.12492 per EA filed
Laurus Labs Limited1$1.12492 per EA filed
Macleods Pharmaceuticals Limited1$1.12492 per EA filed
Teva Pharmaceuticals USA, Inc.1$1.12492 per EA filed
Not listed as a package in the FDA directory1$1.12492 per EA filed
All 7 NDCs, with labeler and price
  • 00093-5234-56 · Teva Pharmaceuticals USA, Inc. · $1.12492 per EA · eff. 2026-09-23 filed
  • 31722-0736-30 · Camber Pharmaceuticals, Inc. · $1.12492 per EA · eff. 2026-09-23 filed
  • 33342-0138-07 · Macleods Pharmaceuticals Limited · $1.12492 per EA · eff. 2026-09-23 filed
  • 42385-0915-30 · Laurus Labs Limited · $1.12492 per EA · eff. 2026-09-23 filed
  • 65862-0497-30 · Aurobindo Pharma Limited · $1.12492 per EA · eff. 2026-09-23 filed
  • 69097-0210-02 · Cipla USA Inc. · $1.12492 per EA · eff. 2026-09-23 filed
  • 76282-0678-30 · not listed as a package in the FDA directory · $1.12492 per EA · eff. 2026-09-23 filed

Compared with its class

The middle of its 7 NDCs’ NADAC prices is $1.12492 per EA filed.

Of the 28 other products in FDA’s Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor class priced per EA, 22 have a higher middle NADAC price and 6 a lower one. The one in the middle is VEMLIDY 25 MG TABLET, at $51.98384 per EA filed (eff. 2026-09-23).

Of the 13 other products in FDA’s Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor class priced per EA, 12 have a higher middle NADAC price and 1 a lower one. The one in the middle is EDURANT 25 MG TABLET, at $48.04095 per EA filed (eff. 2026-09-23).

Of the 28 other products in FDA’s Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor class priced per EA, 22 have a higher middle NADAC price and 6 a lower one. The one in the middle is VEMLIDY 25 MG TABLET, at $51.98384 per EA filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

What Medicare paid

We don’t know yet; the card above says why.

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.